Cogent Biosciences (NASDAQ:COGT – Get Free Report) posted its quarterly earnings results on Monday. The technology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08), MarketWatch Earnings reports. Cogent Biosciences Stock Performance COGT opened at $7.62 on Tuesday. Cogent Biosciences has a fifty-two week low of […]
Cogent Biosciences (NASDAQ:COGT – Get Free Report) announced its quarterly earnings results on Monday. The technology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.08), MarketWatch Earnings reports. Cogent Biosciences Price Performance Shares of Cogent Biosciences stock opened at $7.62 on Tuesday. Cogent Biosciences has a 1 year low […]
22.02.2024 - Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving . Seite 1
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.